BioPharma Dive – AI / Data
Rhythm obesity drug wins broader use from FDA
Imcivree’s clearance in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.
Imcivree’s clearance in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.